These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31889523)

  • 1. Combined Vascular Brachytherapy and Stenting for the Treatment of In-Stent Restenosis.
    Chen Y; Buchanan KD; Chan RC; Zhang C; Torguson R; Satler LF; Waksman R
    Am J Cardiol; 2020 Mar; 125(5):712-719. PubMed ID: 31889523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure.
    Negi SI; Torguson R; Gai J; Kiramijyan S; Koifman E; Chan R; Randolph P; Pichard A; Satler LF; Waksman R
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1259-1265. PubMed ID: 27339842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy.
    Yerasi C; Chen Y; Case BC; Forrestal BJ; Shea C; Zhang C; Torguson R; Ben-Dor I; Satler LF; Waksman R
    Am J Cardiol; 2021 Mar; 142():44-51. PubMed ID: 33285089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular brachytherapy versus drug-eluting stents in the treatment of in-stent restenosis: A meta-analysis of long-term outcomes.
    Benjo A; Cardoso RN; Collins T; Garcia D; Macedo FY; El-Hayek G; Nadkarni G; Aziz E; Jenkins JS
    Catheter Cardiovasc Interv; 2016 Feb; 87(2):200-8. PubMed ID: 25963829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular brachytherapy for patients with drug-eluting stent restenosis.
    Bonello L; Kaneshige K; De Labriolle A; Roy P; Lemesle G; Torguson R; Satler LF; Pichard AD; Lindsay J; Waksman R
    J Interv Cardiol; 2008 Dec; 21(6):528-34. PubMed ID: 18973502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial.
    Alli OO; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA; Holmes DR;
    Am Heart J; 2012 Mar; 163(3):438-45. PubMed ID: 22424015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.
    Rathore S; Kinoshita Y; Terashima M; Katoh O; Matsuo H; Tanaka N; Kimura M; Tsuchikane E; Nasu K; Ehara M; Asakura K; Asakura Y; Suzuki T
    EuroIntervention; 2010 Feb; 5(7):841-6. PubMed ID: 20142201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
    Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
    JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of drug-eluting balloon in patients with bare-metal or drug-eluting stent restenosis.
    Berta B; Jambrik Z; Kohar K; Szabo G; Ruzsa Z; Molnar L; Barczi G; Geller L; Becker D; Merkely B
    Hellenic J Cardiol; 2014; 55(5):369-77. PubMed ID: 25243435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes With Combined Laser Atherectomy and Intravascular Brachytherapy in Recurrent Drug-Eluting Stent In-Stent Restenosis.
    Megaly M; Glogoza M; Xenogiannis I; Vemmou E; Nikolakopoulos I; Omer M; Willson L; Monyak DJ; Sullivan P; Stanberry L; Chavez I; Mooney M; Traverse J; Wang Y; Garcia S; Poulose A; Burke MN; Brilakis ES
    Cardiovasc Revasc Med; 2021 Jan; 22():29-33. PubMed ID: 32571761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term clinical outcomes of brachytherapy, bare-metal stenting, and drug-eluting stenting for de novo and in-stent restenosis lesions: five year follow-up.
    Dogdu O; Yarlioglues M; Kaya MG; Tulumen E; Sarli B; Gunebakmaz O; Ardic I; Kalay N; Akpek M; Kelesoglu S; Basar E
    Cardiol J; 2011; 18(6):654-61. PubMed ID: 22113753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug eluting stents for the treatment of bare metal in-stent restenosis: long-term outcomes in real world practice.
    Appleby CE; Khattar RS; Morgan K; Clarke B; Curzen N; Neyses L; Fath-Ordoubadi F
    EuroIntervention; 2011 Jan; 6(6):748-53. PubMed ID: 21205600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial.
    Ellis SG; O'Shaughnessy CD; Martin SL; Kent K; McGarry T; Turco MA; Kereiakes DJ; Popma JJ; Friedman M; Koglin J; Stone GW;
    Eur Heart J; 2008 Jul; 29(13):1625-34. PubMed ID: 18556716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.